Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin [Internet]. 2025 Mar. 17 [cited 2025 Apr. 5];9(2):s532. Available from: https://skin.dermsquared.com/skin/article/view/3309